ASCO 2023 | PRECIOUS: pertuzumab retreatment in patients with HER2+ breast cancer

Yutaka Yamamoto, MD, PhD, Kumamoto University Hospital, Kumamoto, Japan, describes the trial design of the Phase III PRECIOUS trial (NCT02514681), which assessed pertuzumab retreatment in patients with HER2+ locally advanced/metastatic breast cancer. Patients were randomly assigned to receive trastuzumab and chemotherapy based on physician’s choice with or without pertuzumab retreatment. The primary endpoint was investigator-assessed PFS. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.